TLR9 and neoplasm: After intratumoral administration of DCs with RT, 9 of 17 (52.9%) patients with soft-tissue sarcoma developed a tumor-specific immune response, and there was a remarkable abscopal effect in castration-resistant prostate cancer patients.83,84 LDRT (4 Gy) plus the TLR9 agonist SD-101 led to tumor shrinkage in all patients with indolent lymphoma and nonirradiated tumor shrinkage in 24 of 29 patients.85